Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Lowering serum uric acid levels to prevent kidney failure

According to a recent study, the renoprotective effect of losartan is partly owing to its ability to reduce levels of serum uric acid. This finding, along with supporting evidence from cohort studies, points to lowering of serum uric acid levels as a potential method to prevent end-stage renal disease in patients with diabetes mellitus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rosolowsky, E. T. et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J. Am. Soc. Nephrol. 22, 545–553 (2011).

    Article  CAS  Google Scholar 

  2. Ficociello, L. H. et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 33, 1337–1343 (2010).

    Article  CAS  Google Scholar 

  3. Jalal, D. I. et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol. Dial. Transplant. 25, 1865–1869 (2010).

    Article  CAS  Google Scholar 

  4. Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J. & Parving, H. H. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 58, 1668–1671 (2009).

    Article  CAS  Google Scholar 

  5. Kang, D. H. et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 13, 2888–2897 (2002).

    Article  CAS  Google Scholar 

  6. Johnson, R. J. et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J. Am. Soc. Nephrol. 16, 1909–1919 (2005).

    Article  CAS  Google Scholar 

  7. Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5, 1388–1393 (2010).

    Article  CAS  Google Scholar 

  8. Siu, Y. P., Leung, K. T., Tong, M. K. & Kwan, T. H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47, 51–59 (2006).

    Article  CAS  Google Scholar 

  9. Miao, Y. et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. Hypertension 58, 2–7 (2011).

    Article  CAS  Google Scholar 

  10. Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450–2461 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alessandro Doria.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doria, A., Krolewski, A. Lowering serum uric acid levels to prevent kidney failure. Nat Rev Nephrol 7, 495–496 (2011). https://doi.org/10.1038/nrneph.2011.107

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2011.107

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing